Sanofi-Aventis Removes Thimerosal From Adult Tetanus/Diphtheria Vaccine
This article was originally published in The Pink Sheet Daily
Decavac will be priced at a 78% premium to the discontinued thimerosal-containing version of the vaccine due to additional manufacturing and packaging costs. The company is working with FDA to reduce or remove thimerosal from all its vaccine products.
You may also be interested in...
Report updates 2001 reports that were “unclear” about link between thimerosal and neurodevelopment disorders.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles